Appointments, Successful Clinical Trials, Mergers, and New Contracts Boost Growth - Research Report on BioMarin, ARIAD, Bard,

  Appointments, Successful Clinical Trials, Mergers, and New Contracts Boost
   Growth - Research Report on BioMarin, ARIAD, Bard, Rockwell Medical, and
                                  Health Net

PR Newswire

NEW YORK, September 9, 2013

NEW YORK, September 9, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting BioMarin
Pharmaceutical Inc. (NASDAQ: BMRN), ARIAD Pharmaceuticals, Inc. (NASDAQ:
ARIA), C.R. Bard, Inc. (NYSE: BCR), Rockwell Medical Inc. (NASDAQ: RMTI), and
Health Net Inc. (NYSE: HNT). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

BioMarin Pharmaceutical Inc. Research Report

On September 3, 2013, BioMarin Pharmaceutical Inc. (BioMarin) announced that
Richard Ranieri has been appointed as Senior Vice President, Human Resources
and Corporate Affairs, with effect from September 4, 2013. According to the
Company, prior to joining BioMarin Mr. Ranieri served as the Executive Vice
President, Human Resources at Dendreon Corporation from 2010 to 2013, where he
was responsible for the HR function and oversaw the expansion of the workforce
from 150 to 2000 employees. Jean-Jacques Bienaimé, CEO of BioMarin, said, "We
are very pleased to welcome Rich to BioMarin. He brings a wealth of human
resources experience to the company as we continue our rapid growth. He has
the depth and breadth of global experience that BioMarin needs as it scales
its operations to meet its expanding business." The Full Research Report on
BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-04/BMRN]

--

ARIAD Pharmaceuticals, Inc. Research Report

On September 4, 2013, ARIAD Pharmaceuticals, Inc. (ARIAD) announced that it
has achieved enrollment of 50% of the patients planned for ARIAD's randomized
Phase 3 trial of Iclusig (ponatinib) in adult patients with newly diagnosed
chronic myeloid leukemia (CML). According to the Company, the said trial,
which was earlier known as EPIC, aimed to provide definitive clinical data to
support regulatory approval of ponatinib in treatment-naïve CML patients.
ARIAD stated that an interim analysis of efficacy, mainly with a primary
endpoint of major molecular response rate (MMR) of twelve months, will be
performed in Q3 2014 based on the patients enrolled to date. The Company
anticipates reaching its target of enrolling 500 patients in the trial by the
end of 2013. The Full Research Report on ARIAD Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-04/ARIA]

--

C.R. Bard, Inc. Research Report

On September 4, 2013, C.R. Bard, Inc. (Bard) announced that the Company has
entered into a definitive agreement to acquire Rochester Medical Inc.
(Rochester Medical) - a developer and supplier of silicone urinary
incontinence and urine drainage products, for a price of $20 per share or
c.$262 million in the aggregate to be paid at closing, which Bard expects
later in 2013. According to Bard, this acquisition will enhance its position
in the $930 million global urology homecare market. Timothy M. Ring, Bard's
chairman and CEO, commented, "Rochester's double-digit growth product
portfolio, including their customer access programs, is a key building block
in our strategy to access faster growing markets over the long-term. We
believe that strengthening our position in the home care market, and
specifically the large and fast-growing intermittent self-catheter segment, is
strategically important at this time." Bard informed that the transaction,
structured as a merger, has been approved by the Board of Directors of both
the Companies, and is subject to customary closing conditions, including the
approval of the shareholders of Rochester Medical and regulatory approvals.
The Full Research Report on C.R. Bard, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-09-04/BCR]

--

Rockwell Medical Inc. Research Report

On September 4, 2013, Rockwell Medical Inc. (Rockwell Medical) announced
successful top-line results from the long-term CRUISE-2 Phase 3 efficacy study
of SFP, a late-stage investigational iron-delivery drug for the treatment of
iron deficiency in chronic kidney disease patients receiving hemodialysis.
Rockwell Medical stated that SFP met the primary endpoint, demonstrating a
statistically significant mean change in hemoglobin from baseline to
End-of-Treatment. Further, Rockwell revealed that SFP met key secondary
endpoints, including maintenance of hemoglobin, maintenance of reticulocyte
hemoglobin, and increase in serum iron pre-to-post treatment without an
increase in ferritin. This study is the second and final study of two
identical Phase 3 efficacy studies to provide the clinical data to allow
Rockwell Medical to file a New Drug Application (NDA) with the US FDA. The
Full Research Report on Rockwell Medical Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-09-04/RMTI]

--

Health Net Inc. Research Report

On September 4, 2013, Health Net Federal Services, LLC, (Health Net Federal
Services), a wholly owned subsidiary of Health Net Inc. (Health Net),
announced that the Department of Veterans Affairs (VA) has awarded a contract
to the Company under its new Patient Centered Community Care program. The
Company informed that with this contract, eligible Veterans will be able to
receive coordinated, timely access to care through a comprehensive network of
non-VA providers who meet VA quality standards when a local VA Medical Center
cannot readily provide the care. According to Health Net Federal Services, it
will support VA in caring veterans of the three (out of six) Patient Centered
Community Care Regions namely: 1, 2, and 4, which cover all or portions of 37
states, Puerto Rico, and the Virgin Islands. The Full Research Report on
Health Net Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-04/HNT]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by an analyst. However, we are only human and are prone
    to make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports

Contact: Kristi Saunders CONTACT PHONE: +1-315-982-6420 (North America)